| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | 2025/Q3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 1.361.774.980 $ | +396.579.536 $ | +61,3 % | 10 | 973.477.227 $ | +359.293.159 $ | +59,3 % | 9 | 583.523.038 $ | +135.843.869 $ | +39,3 % | 6 | ||||
| Revolution Medicines, Inc. | RVMD | → 0 | Schwach | 739.205.711 $ | +133.779.131 $ | +22,1 % | 1 | 605.426.580 $ | +250.455.817 $ | +70,6 % | 1 | 354.970.763 $ | +75.326.772 $ | +26,9 % | 1 |
| Tyra Biosciences, Inc. | TYRA | → 0 | Schwach | 155.339.476 $ | +48.710.890 $ | +45,7 % | 1 | 106.628.586 $ | +49.887.091 $ | +87,9 % | 1 | 56.741.495 $ | +17.926.905 $ | +46,2 % | 1 |
| Tango Therapeutics, Inc. | TNGX | → 0 | Neutral | 152.006.415 $ | +87.628.937 $ | +136,1 % | 1 | 64.377.478 $ | +17.892.046 $ | +38,5 % | 1 | 46.485.432 $ | +18.151.454 $ | +64,1 % | 1 |
| Oric Pharmaceuticals, Inc. | ORIC | → 0 | Neutral | 90.750.611 $ | +32.160.240 $ | +54,9 % | 1 | 58.590.371 $ | -27.361.273 $ | -31,8 % | 1 | 85.951.644 $ | +13.250.878 $ | +18,2 % | 1 |
| ALUMIS INC. | ALMS | → 0 | Neutral | 78.008.186 $ | +49.548.046 $ | +174,1 % | 1 | 28.460.140 $ | +16.825.308 $ | +144,6 % | 1 | ||||
| Relay Therapeutics, Inc. | RLAY | → 0 | Schwach | 54.988.735 $ | +15.213.994 $ | +38,3 % | 1 | 39.774.741 $ | +19.696.486 $ | +98,1 % | 1 | 20.078.255 $ | +6.769.680 $ | +50,9 % | 1 |
| Zymeworks Inc. | ZYME | → 0 | Neutral | 27.893.208 $ | -1.436.990 $ | -4,9 % | 1 | 29.330.198 $ | +10.304.000 $ | +54,2 % | 1 | ||||
| Kymera Therapeutics, Inc. | KYMR | → 0 | Schwach | 23.229.248 $ | +1.528.350 $ | +7,0 % | 1 | 21.700.898 $ | +2.405.449 $ | +12,5 % | 1 | 19.295.449 $ | +4.418.180 $ | +29,7 % | 1 |
| CytomX Therapeutics, Inc. | CTMX | → 0 | Schwach | 20.914.680 $ | +20.914.680 $ | 1 | |||||||||
| Context Therapeutics Inc. | CNTX | → 0 | Neutral | 19.438.710 $ | +8.532.258 $ | +78,2 % | 1 | ||||||||
| enGene Therapeutics Inc. | ENGN | → 0 | Schwach | 19.188.235 $ | +19.188.235 $ | 1 | |||||||||
| 1.361.774.980 $ | +396.579.536 $ | +61,3 % | 10 | 973.477.227 $ | +359.293.159 $ | +59,3 % | 9 | 583.523.038 $ | +135.843.869 $ | +39,3 % | 6 | ||||